Periodontal DiseasesNCT06465095
Evaluation of Inflammasome Gene Polymorphisms in Periodontitis Patients
An observational study of Periodontal Diseases and Periodontitis, run by Marmara University at 1 site in Turkey (Türkiye).
Trial summary
The present study aimed to evaluate the distribution of NLRP3, AIM2, and IFI16 inflammasome gene polymorphisms in individuals with Stage III Grade B and C periodontitis and periodontally healthy individuals. Read more about this study
- Who is it for?
- Ages 18 to 65 yearsHealthy volunteers can take part
- Conditions the study is for
- Periodontal Diseases, Periodontitis
- What is being tested?
- Baseline
- How many people
- 240 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 1 Jul 2024to 14 Apr 2025
- How long will I take part?
- 1 Day
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Sistemically healthy, non-smokers. Periorodontally healthy, stage III perodontitis B and C periodontitis patients.
Who may be able to join
- systematically healthy, non-smoker individuals
- patients between the ages of 18 and 65
- individuals with periodontally healthy, stage III grade B and C periodontitis diagnoses
Who cannot join
- having any diagnosed medical disorders such as diabetes mellitus, cardiovascular diseases, rheumatoid arthritis...
- Usage of antibiotics, non-steroidal anti-inflammatory drugs and immunosuppressive agents within the past 6 months.
- Periodontal treatment within the preceding 6 months.
- Pregnant/ lactating/ postmenopausal females.
- Current orthodontic treatment.
Trial locations and contacts
1 site in 1 country.
Turkey (Türkiye)1 site, 1 recruiting
- Recruiting
Marmara University
Istanbul, Maltepe, 34854
Hafize Öztürk Özener, 3765376, hafize.ozturk@marmara.edu.tr
About this study
Official title: Evaluation of Inflammasome Gene Polymorphisms in Patients With Stage III, Grade B and C Periodontitis
The present study aimed to evaluate the distribution of NLRP3, AIM2, and IFI16 inflammasome gene polymorphisms in individuals with Stage III Grade B and C periodontitis and periodontally healthy individuals. 80 periodontally healthy, 80 Stage III Grade B and 80 Stage III Grade C periodontitis patients will be enrolled. Blood samples will be collected from each participants and clinical parameteres will be recorded for whole mouth. DNA isolation will be performed from all samples. The SNP regions with the numbers rs4612666, rs75985579, and rs2793845 will be detected from DNA material using Real-Time PCR device genotyping kits. Data will be analyzed using statistical tests.
Read the detailed description
Innate immune response is the first line of defense mechanism of the body against pathogens. One of the most important proteins involved in the innate immune response are the inflammasomes which are multimeric protein complexes composed of a sensor molecule (the PRR), typically the adapter molecule apoptosis-associated speck-like protein containing a caspase-recruitment domain (CARD), and the protease caspase-1. Different types of inflammasomes have been described. In periodontal disease, inflammasome activation is associated with the release of pro-inflammatory cytokines, which can lead to tissue destruction and periodontal damage.
Progression rate, onset age, and severity of periodontal disease are influenced by some modifiable or non-modifiable risk factors present in the host. Genetic polymorphisms are non-modifiable risk factors for periodontitis. Variations in inflammasome genes may be determinants in the development of periodontal disease by leading to diversity in inflammatory markers.
Sample size is determined based on a previous study which analyzes the effect of NLRP3 gene polymorphism on periodontitis susceptibility. For rs4612666 group, with an α value of 0.05 and a power of 80%, it is determined that there should be 80 participants in each group. Totally 240 patients are included (80 periodontally healthy, 80 Stage III Grade B periodontitis, 80 Stage III Grade C periodontitis). The whole mouth clinical periodontal examination includes measurement of probing depth (PPD), clinical attachment level (CAL), presence of bleeding on probing (BOP), gingival index (GI), and plaque index (PI) at 6 sites per tooth, except the third molars. Periodontal diagnosis of each patient has been made according to the 2017 World Workshop on Classification of Periodontal and Peri-Implant Diseases and Conditions. Healthy group includes individuals without a clinical inflammation pattern and a history of periodontitis, with no detected clinical attachment and bone loss, BOP < 10%, probing depth ≤ 3 mm. Stage III Grade B periodontitis patients have minimum of 20 teeth (except third molars), with CAL ≥ 5 mm, probing depth ≥ 6mm, and radiographically showing bone loss extending up to one-third of the root, percantage of bone lose by age is 0.25-1 and Stage III Grade C patients have minimum of 20 teeth (except third molars), with CAL ≥ 5 mm, probing depth ≥ 6mm, and radiographically showing bone loss extending up to one-third of the root, percantage of bone lose by age is >1.
Sample Collection and DNA Isolation and Genotyping A total of 5 mL of blood is collected from the antecubital fossa by venepuncture method from each participants and stored at -80°C until analysis day. DNA isolation has been made using genomic DNA kits. rs4612666, rs75985579, and rs2793845 SNP regions are detected from DNA material using Real-Time PCR device genotyping kits.
Statistical analysis has been performed with standard statistical software package by selecting appropriate tests.
- Conditions
- Periodontal Diseases, Periodontitis
- Being tested
- Baseline
- Keywords
- Periodontitis, gene, polymorphism
- Medical subject headings
- Periodontal Diseases, Periodontitis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
BaselineGenetic
Measurements and sampling
| Study group | Role | What they receive |
|---|---|---|
| Healthy | Individuals without a clinical inflammation pattern and a history of periodontitis, with no detected clinical attachment and bone loss, BOP < 10%, probing depth ≤ 3 mm. Receives: Genetic: Baseline | |
| Stage III Grade B Periodontitis | Individuals that have minimum of 20 teeth (except third molars), with CAL ≥ 5 mm, probing depth ≥ 6mm, and radiographically showing bone loss extending up to one-third of the root, percantage of bone lose by age is 0.25-1 will be included. Receives: Genetic: Baseline | |
| Stage III Grade C Periodontitis | Individuals that have minimum of 20 teeth (except third molars), with CAL ≥ 5 mm, probing depth ≥ 6mm, and radiographically showing bone loss extending up to one-third of the root, percantage of bone lose by age is >1 will be included. Receives: Genetic: Baseline |
What is being measured
The primary outcome is the main question the study is designed to answer.
NLRP3 gene polymorphism
SNP
Measured: Baseline
Secondary outcomes (2)
AIM2 gene polymorphism
SNP
Measured: Baseline
IFI16
SNP
Measured: Baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Jun 2024
- Study start1 Jul 2024
- Primary completion14 Apr 2025 (estimated)
- Study completion14 Apr 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Periodontal DiseasesStudies of the same condition, open and under way.
- More trials run by Marmara UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Enrolment
- 240 participants (estimated)
- Target duration
- 1 Day
Sponsor and investigators
- Lead sponsor
- Marmara University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06465095
- Sponsor's protocol ID
- 09-2023-1700
- Status last verified
- Feb 2024
- First submitted
- 13 Jun 2024
- Last updated
- 16 Aug 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Saka N, Yilmaz OO, Tacal Aslan B, Ozturk Ozener H. The role of NLRP3, AIM2, and IFI16 gene polymorphisms in periodontitis susceptibility: a case control study. BMC Oral Health. 2026 Feb 3;26(1):432. doi: 10.1186/s12903-026-07740-w.
PubMed 41634660
Study at a glance
From the registry record, last updated by the sponsor on 16 Aug 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of Inflammasome Gene Polymorphisms in Patients With Stage III, Grade B and C Periodontitis
- ClinicalTrials.gov ID
- NCT06465095
- Acronym / sponsor ID
- 09-2023-1700
- Conditions
- Periodontal Diseases, Periodontitis
- Keywords
- Periodontitis, gene, polymorphism
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 240 participants (estimated)
- Lead sponsor
- Marmara UniversityUniversity, hospital or other
- Study start
- 1 Jul 2024 (actual)
- Primary completion
- 14 Apr 2025 (estimated)
- Study completion
- 14 Apr 2025 (estimated)
- First posted
- 18 Jun 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The present study aimed to evaluate the distribution of NLRP3, AIM2, and IFI16 inflammasome gene polymorphisms in individuals with Stage III Grade B and C periodontitis and periodontally healthy individuals. 80 periodontally healthy, 80 Stage III Grade B and 80 Stage III Grade C periodontitis patients will be enrolled. Blood samples will be collected from each participants and clinical parameteres will be recorded for whole mouth. DNA isolation will be performed from all samples. The SNP regions with the numbers rs4612666, rs75985579, and rs2793845 will be detected from DNA material using Real-Time PCR device genotyping kits. Data will be analyzed using statistical tests.
Detailed description
Innate immune response is the first line of defense mechanism of the body against pathogens. One of the most important proteins involved in the innate immune response are the inflammasomes which are multimeric protein complexes composed of a sensor molecule (the PRR), typically the adapter molecule apoptosis-associated speck-like protein containing a caspase-recruitment domain (CARD), and the protease caspase-1. Different types of inflammasomes have been described. In periodontal disease, inflammasome activation is associated with the release of pro-inflammatory cytokines, which can lead to tissue destruction and periodontal damage.
Progression rate, onset age, and severity of periodontal disease are influenced by some modifiable or non-modifiable risk factors present in the host. Genetic polymorphisms are non-modifiable risk factors for periodontitis. Variations in inflammasome genes may be determinants in the development of periodontal disease by leading to diversity in inflammatory markers.
Sample size is determined based on a previous study which analyzes the effect of NLRP3 gene polymorphism on periodontitis susceptibility. For rs4612666 group, with an α value of 0.05 and a power of 80%, it is determined that there should be 80 participants in each group. Totally 240 patients are included (80 periodontally healthy, 80 Stage III Grade B periodontitis, 80 Stage III Grade C periodontitis). The whole mouth clinical periodontal examination includes measurement of probing depth (PPD), clinical attachment level (CAL), presence of bleeding on probing (BOP), gingival index (GI), and plaque index (PI) at 6 sites per tooth, except the third molars. Periodontal diagnosis of each patient has been made according to the 2017 World Workshop on Classification of Periodontal and Peri-Implant Diseases and Conditions. Healthy group includes individuals without a clinical inflammation pattern and a history of periodontitis, with no detected clinical attachment and bone loss, BOP < 10%, probing depth ≤ 3 mm. Stage III Grade B periodontitis patients have minimum of 20 teeth (except third molars), with CAL ≥ 5 mm, probing depth ≥ 6mm, and radiographically showing bone loss extending up to one-third of the root, percantage of bone lose by age is 0.25-1 and Stage III Grade C patients have minimum of 20 teeth (except third molars), with CAL ≥ 5 mm, probing depth ≥ 6mm, and radiographically showing bone loss extending up to one-third of the root, percantage of bone lose by age is >1.
Sample Collection and DNA Isolation and Genotyping A total of 5 mL of blood is collected from the antecubital fossa by venepuncture method from each participants and stored at -80°C until analysis day. DNA isolation has been made using genomic DNA kits. rs4612666, rs75985579, and rs2793845 SNP regions are detected from DNA material using Real-Time PCR device genotyping kits.
Statistical analysis has been performed with standard statistical software package by selecting appropriate tests.
Study design
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Target follow-up
- 1 Day
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Healthy | – | Genetic: BaselineIndividuals without a clinical inflammation pattern and a history of periodontitis, with no detected clinical attachment and bone loss, BOP < 10%, probing depth ≤ 3 mm. |
| Stage III Grade B Periodontitis | – | Genetic: BaselineIndividuals that have minimum of 20 teeth (except third molars), with CAL ≥ 5 mm, probing depth ≥ 6mm, and radiographically showing bone loss extending up to one-third of the root, percantage of bone lose by age is 0.25-1 will be included. |
| Stage III Grade C Periodontitis | – | Genetic: BaselineIndividuals that have minimum of 20 teeth (except third molars), with CAL ≥ 5 mm, probing depth ≥ 6mm, and radiographically showing bone loss extending up to one-third of the root, percantage of bone lose by age is >1 will be included. |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Sistemically healthy, non-smokers. Periorodontally healthy, stage III perodontitis B and C periodontitis patients.
Key inclusion criteria (3 listed)
- systematically healthy, non-smoker individuals
- patients between the ages of 18 and 65
- individuals with periodontally healthy, stage III grade B and C periodontitis diagnoses
Key exclusion criteria (5 listed)
- having any diagnosed medical disorders such as diabetes mellitus, cardiovascular diseases, rheumatoid arthritis...
- Usage of antibiotics, non-steroidal anti-inflammatory drugs and immunosuppressive agents within the past 6 months.
- Periodontal treatment within the preceding 6 months.
- Pregnant/ lactating/ postmenopausal females.
- Current orthodontic treatment.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| BaselineMeasurements and sampling | Genetic | Healthy, Stage III Grade B Periodontitis, Stage III Grade C Periodontitis |
Primary outcome
NLRP3 gene polymorphism
Time frame: Baseline
SNP
2 secondary outcomes
AIM2 gene polymorphism
Time frame: Baseline
IFI16
Time frame: Baseline
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Aug 2024.
- Derived from this study: PubMed 41634660Saka N, Yilmaz OO, Tacal Aslan B, Ozturk Ozener H. The role of NLRP3, AIM2, and IFI16 gene polymorphisms in periodontitis susceptibility: a case control study. BMC Oral Health. 2026 Feb 3;26(1):432. doi: 10.1186/s12903-026-07740-w.
Related trials for Periodontal Diseases
Not yet recruitingObservational study
Periodontal Status and Biomarkers in MASLD
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Recruiting
Thermosensitive Hyaluronic Gel With Octenidine as an Adjunctive to Subgingival Instrumentation
Periodontal Disease
Active, not recruitingObservational study
A Retrospective Comparative Evaluation of Omega-3 and Resveratrol Supplementation in Patients With Periodontitis
Periodontitis
Recruiting
Effects of Different Activation Techniques on Antimicrobial Photodynamic Therapy in Apical Periodontitis
Apical Periodontitis, Endodontic Retreatment
Recruiting
Ozone Gel Versus Chlorohexidine Gel as an Adjunct to Non-Surgical Treatment of Stage II Periodontitis Grade B Among Smokers Patients
Ozone Gel, Chlorohexidine Gel
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Periodontal Diseases and Periodontitis, run by Marmara University at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 16 Aug 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
NLRP3 gene polymorphism (time frame: Baseline). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06465095, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Aug 2024.